DOTATATE PET for Meningioma Radiation Planning

NCT06937268 — Not applicable, Not yet recruiting, 36 participants, British Columbia Cancer Agency

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning

Registry	NCT06937268, acronym DOTATATE-RT
Status	Not yet recruiting
Phase	Not applicable
Study type	Interventional; na, single group, masking: none, treatment
Enrollment	36 (Estimated)
Sponsor	British Columbia Cancer Agency (Other)
Conditions	Meningioma
Interventions	DOTATATE-PET scan (Diagnostic test)
Dates	start 2025-06-01 (estimated), primary completion 2026-12-31 (estimated), completion 2027-12-31 (estimated), first posted 2025-04-22, last updated 2025-04-22
Locations	1 site in Canada

-Summary

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
DOTATATE-PET scan	Experimental	Diagnostic Test: DOTATATE-PET scan

DOTATATE-PET scan (Diagnostic test): DOTATATE tracer PET scan for meningioma

+Outcome measures

Primary outcomes

Target radiation volume [2 years]: The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan

Secondary outcomes

Local control [2 years]
Progression-free survival [2 years]
Perceived usefulness by radiation oncologist [2 years]
Adverse event [2 years]
Rate of DOTATATE-scan completion [2 years]
Extent of post-operative disease volume compared to MRI [2 years]
Overall survival [2 years]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age ≥ 18 years old
* Able and willing to comply with the study procedures
* Intact meningioma requiring definitive radiation
* Post-operative meningioma requiring adjuvant radiation
* No prior radiation therapy or medical therapy directed at the tumour

Exclusion Criteria:

* Breastfeeding or pregnancy
* Claustrophobia or inability to lie still in a supine position
* Unwillingness or inability to provide informed consent

+Locations (1)

Facility	City	Country	Status
BC Cancer - Vancouver	Vancouver, British Columbia	Canada